에임드바이오

0009K0KOSDAQ자연과학 및 공학 연구개발업

49.4 / 100

Reference Date: 2026-07-24

Financial Score17.5 / 40

News Sentiment18.9 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 13.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

AimedBio is a global biotech company specializing in the development of antibody-drug conjugate (ADC)-based anticancer therapeutics, leveraging patient-derived models and proprietary linker-payload technology. As a spin-off from Samsung Seoul Hospital, the company has achieved milestones through technology transfers and co-development agreements with global pharmaceutical firms since 2024.

Number of Employees

52people

Average Salary

69.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

201.85Industry Average 43.640.0Point

4.6x industry avg (risky)

PBR

7.32Industry Average 2.520.0Point

2.9x industry avg (risky)

ROE

5.12Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

0.37Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 6.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

3.0 / 4

Detailed News Sentiment

11 totalPositive 8Neutral 3Negative 0Average Sentiment Score 75.5

Positive
에임드바이오 “기술이전한 FGFR3 ADC, 임상 1상서 객관적 반응 ...
에임드바이오의 기술이전 ADC 후보물질 AMB302가 임상 1상에서 객관적 반응을 보여 긍정적인 임상 결과를 나타냈다.
Positive
에임드바이오 기술이전 신약, 임상 1상서 종양 감소 효과 확인
에임드바이오의 ADC 기반 신약이 임상 1상에서 종양 감소 효과를 보여 긍정적인 신호를 제공했다.
Neutral
과기정통부, 국가신약개발단 간담회 개최…“성과 중심 지원 강화”
정부의 국가신약개발사업 지원 강화 발표는 관련 산업에 긍정적 영향을 미칠 수 있으나, 직접적인 영향은 제한적임.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 21,800Won52-week high 72,50052-week low 19,350

1-month return1.0Point

1m -12.97% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (BI 4060107 (ODS025)의 제 1상 임상시험계획 승인 신청)2026-07-22
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-07-16
Neutral임시주주총회결과2026-07-16
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (BI 4060107 (ODS025)의 제 1상 임상시험계획 승인 신청)2026-07-15
Neutral주주총회소집공고2026-07-01